(DIR) Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
 (HTM) https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
 (DIR) MS Speaks
       *****************************************************
 (DIR) Higher severe COVID-19 risk for patients on Ocrevus, Rituxan
       1 replies
 (DIR) Fatal PML case in 78-year-old patient on Ocrevus monotherapy
       3 replies
 (DIR) (Abst.) Ocrelizumab depletes T-lymphocytes more than rituximab...
       0 replies
 (DIR) (Abst.) Shorter infusion time of ocrelizumab...
       1 replies
 (DIR) (ACTRIMS/ECTRIMS) Some MS drugs linked with worse COVID-19 out...
       0 replies
 (DIR) (Abst.) Effect of Ocrevus on vaccine responses in patients w/MS
       0 replies
 (DIR) (Abst.) Adverse event profile differences between Rituxan and ...
       1 replies
 (DIR) (Abst.) Varicella zoster immunity loss in MS patient treated w...
       0 replies
 (DIR) (Abst.) Switching to Ocrevus in RRMS patients at risk of PML p...
       0 replies
 (DIR) 2-hour Ocrevus infusion time OK'd in Europe
       0 replies
       *****************************************************
 (DIR) Previous Page
 (DIR) Next Page